Findings

What do systematic reviews say?

7 questions · 7 findings · 1 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 3 · 42.9%High 4 · 57.1%

Certolizumab pegol 200 mg sc (with or without MTX) vs placebo (with or without MTX)

Acceptability: total withdrawals · patients with rheumatoid arthritis in adults

Certolizumab pegol 200 mg sc (with or without MTX) probably leads to lower all Withdrawals: All doses of certolizumab pegol vs placebo compared with placebo (with or without MTX) (moderate certainty).

1 finding from 1 review

Certolizumab pegol (CDP870) for rheumatoid arthritis in adults 2017 · Cochrane Headline outcomes only
RR 0.47 [0.39, 0.56]
13 studies · 5200 participants
Moderate

Certolizumab pegol 200 mg sc (with or without MTX) vs placebo (with or without MTX)

Withdrawals due to adverse events · patients with rheumatoid arthritis in adults

Certolizumab pegol 200 mg sc (with or without MTX) leads to higher withdrawals due to adverse events All doses of certolizumab pegol… compared with placebo (with or without MTX) (high certainty).

1 finding from 1 review

Certolizumab pegol (CDP870) for rheumatoid arthritis in adults 2017 · Cochrane Headline outcomes only
Peto OR 1.45 [1.09, 1.94]
12 studies · 5236 participants
High

Certolizumab pegol 200 mg sc (with or without MTX) vs placebo (with or without MTX)

ACR 50% improvement · patients with rheumatoid arthritis in adults

Certolizumab pegol 200 mg sc (with or without MTX) leads to higher ACR 50% improvement compared with placebo (with or without MTX) (high certainty).

1 finding from 1 review

Certolizumab pegol (CDP870) for rheumatoid arthritis in adults 2017 · Cochrane Headline outcomes only
RR 3.8 [2.42, 5.95]
5 studies · 1445 participants
High

Certolizumab pegol 200 mg sc (with or without MTX) vs placebo (with or without MTX)

HAQ change from baseline Scale from: 0 to 3. · patients with rheumatoid arthritis in adults

Certolizumab pegol 200 mg sc (with or without MTX) showed no clear difference in HAQ change from baseline Scale from: 0 to 3. compared with placebo (with or without MTX) (moderate certainty).

1 finding from 1 review

Certolizumab pegol (CDP870) for rheumatoid arthritis in adults 2017 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 1268 participants
Moderate

Certolizumab pegol 200 mg sc (with or without MTX) vs placebo (with or without MTX)

DAS (low or remission) · patients with rheumatoid arthritis in adults

Certolizumab pegol 200 mg sc (with or without MTX) leads to higher proportion of patients achieving DAS < 2.6 (remission) compared with placebo (with or without MTX) (high certainty).

1 finding from 1 review

Certolizumab pegol (CDP870) for rheumatoid arthritis in adults 2017 · Cochrane Headline outcomes only
RR 2.94 [1.64, 5.28]
6 studies · 2420 participants
High

Certolizumab pegol 200 mg sc (with or without MTX) vs placebo (with or without MTX)

Radiological changes: Erosion Scores (ES) Scale from: 0 to 230. · patients with rheumatoid arthritis in adults

Certolizumab pegol 200 mg sc (with or without MTX) showed no clear difference in radiological changes: Erosion Scores (ES) Scale from: 0 to 230 compared with placebo (with or without MTX) (moderate certainty).

1 finding from 1 review

Certolizumab pegol (CDP870) for rheumatoid arthritis in adults 2017 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 714 participants
Moderate

Certolizumab pegol 200 mg sc (with or without MTX) vs placebo (with or without MTX)

Serious adverse events · patients with rheumatoid arthritis in adults

Certolizumab pegol 200 mg sc (with or without MTX) leads to higher serious adverse events compared with placebo (with or without MTX) (high certainty).

1 finding from 1 review

Certolizumab pegol (CDP870) for rheumatoid arthritis in adults 2017 · Cochrane Headline outcomes only
Peto OR 1.47 [1.13, 1.91]
9 studies · 3927 participants
High